Table 2.

The diagnostic performance of ADAM12, CHI3L1, MMP13, SPP1 and their combination (Logit(p=ESCC)=-4.583+0.017×CHI3L1+0.018×SPP1+0.821×MMP13) in discriminating ESCC, early stage ESCC and controls (healthy controls and patients with esophageal benign disease) in the test cohort and validation cohort.

Markers(ng/ml)	AUC	Cut-off	Sen (%)	Spe (%)	PPV (%)	NPV (%)
ESCC in the test cohort
ADAM12	0.646	0.068	90	29.29	57.69	73.21
CHI3L1	0.732	33.100	90	25.71	56.49	70.59
MMP13	0.881	0.438	90	57.86	69.59	84.38
SPP1	0.661	23.920	90	15.00	53.15	58.33
Combination	0.928	0.282	90	72.14	77.59	87.07
Early Stage ESCC in the test cohort
CHI3L1	0.681	33.100	83.10	25.71	36.20	75.00
MMP13	0.866	0.438	88.73	57.86	51.64	91.01
SPP1	0.639	23.920	84.51	15.00	33.52	65.63
Combination	0.918	0.282	90.14	72.14	62.14	93.52
ESCC in the validation cohort
CHI3L1	0.753	33.100	89.35	29.87	58.30	71.88
MMP13	0.789	0.438	91.12	44.81	64.43	82.14
SPP1	0.696	23.920	80.47	25.97	54.40	54.79
Combination	0.843	0.282	84.02	69.48	75.13	79.85
Early Stage ESCC in the validation cohort
CHI3L1	0.757	33.100	89.29	29.87	40.98	83.63
MMP13	0.806	0.438	92.86	44.81	47.85	92.00
SPP1	0.675	23.920	79.76	25.97	37.02	70.18
Combination	0.857	0.282	90.48	69.48	61.79	93.04

Abbreviations: ESCC:esophageal squamous cell carcinoma; Sen, sensitivity; Spe, specificity; PPV, positive predictive value; NPV, negative predictive value; HC,healthy control.